Aliceblue ANTInstall and trade smarter everywhere
Complete IPO details, including price band, financials, subscription status, and key insights.
Participate in the Sai Life Sciences Ltd IPO with full transparency. Review issue details, company fundamentals, and financial performance, and apply securely through Alice Blue.
Key metrics and details at a glance.
Price Band
₹549
Per ShareLot Size
27 Shares
Minimum Investment
₹14,823
Issue Size
₹3,042.62 Cr
Face Value
₹1
Per ShareIPO Type
Book Building
Retail Quota
35%
QIB Quota
50%
NII Quota
15%
Important dates for your applying strategy.
Business model, operations, and market positioning.
Promoter Holding (Pre-Issue)
41.46%
Promoter Holding (Post-Issue)
35.24%
Issue Type
Book Building
ISIN
INE570L01029
We are a pure play fully-integrated, innovator-focused, contract research, development and manufacturing organization. We provide end-to-end services across the drug discovery, development and manufacturing value chain for small molecule new chemical entities to global pharmaceutical innovators companies and biotechnology firms. We possess both (a) discovery / contract research and (b) chemistry, manufacturing, and control / contract development and manufacturing organization capabilities. We have research laboratories for discovery and development located near overseas innovation hubs at Watertown (Greater Boston, MA), US and Manchester, UK, complemented by large-scale research laboratories and manufacturing facilities in cost competitive locations in India.
The global small molecule contract research, development and manufacturing organization industry is forecasted to reach US$159 billion by 2028 (comprising approximately 53% of the overall global contract research, development and manufacturing organization industry), driven by increasing pharmaceutical and biotech research & development outsourcing, continued demand for small molecules and growing demand for cost-effective drugs. The Indian contract research, development and manufacturing organization market was among the fastest growing markets in Asia Pacific region over 2018-2023. The Indian market is projected to grow by 14.0% between 2023 and 2028, reaching an estimated value of US$14.1 billion in 2028. Revenue Model of the Company: Our fee arrangement is primarily based on two types of models: (i) fee-for-service ("FFS") model and (ii) full-time equivalent ("FTE") model. As of September 30, 2024, 35.40% and 64.60% of our contracts with customers are based on FFS model and FTE model, respectively. (i) FTE Model: Through FTE contracts, we offer services to our customers with dedicated resources. We execute work based on our customers' scope and bill for the number of resources engaged along with pass through costs on monthly basis. (ii) FFS Model Under the FFS model, we work based on purchase orders as well as long-term supply agreements with our customers to manufacture and deliver APIs or intermediates as per their requirements over multi-year periods. We also take on projects to produce and deliver specified quantities of materials as required by our customers. Furthermore, the table below sets forth the revenue split between our CRO and CDMO services, including as a percentage of our revenue from contract research, development and manufacturing activities, for the periods indicated.
Revenue, profit after tax and total assets across the last 3 reported financial years.
Amount in ₹ crore
How the company plans to utilize IPO proceeds.
The funds raised through this IPO will be used for:
Initial public offering of 55,421,123 equity shares of face value of Re. 1 each ("Equity Shares") of Sai Life Sciences Limited (The "Company" or the "Company") for cash at a price of Rs. 549 per equity share (including a premium of Rs. 548 per equity share) ("Offer Price") aggregating to Rs. 3042.62 crores (the "Offer") comprising a fresh issue of 17,304,189 equity shares of face value of Re. 1 each aggregating to Rs. 950.00 crores (the "Fresh Issue") and an offer for sale of 38,116,934 equity shares of face value of Re. 1 each aggregating to Rs. 2092.62 crores (the "Offer for Sale"), consisting of 6,454,780 equity shares of face value of Re. 1 each aggregating to Rs. 354.37 crores by Sai Qest Syn Private Limited ("Promoter Selling Shareholder"), 23,159,368 equity shares of face value of Re. 1 each aggregating to Rs. 1271.45 crores by tpg asia vii sf pte ltd ("TPG"), 6,210,186 equity shares of face value of Re. 1 each aggregating to Rs. 340.94 crores by hbm private equity india (collectively with tpg, "Investor Selling Shareholders") and 2,292,600 equity shares of face value of Re. 1 each aggregating to Rs. 125.86 crores by certain persons listed in this prospectus (the "Other Selling Shareholders", as defined below) (the promoter selling shareholder, investor selling shareholders and other selling shareholders, the "Selling Shareholders" and such equity shares, the "Offered Shares").
*Subject to approvals and market conditions.
Key competitive advantages and factors to consider before investing.
Live demand across investor categories.
Track real-time subscription levels:
*Real-time data subject to exchange updates
Our Company was originally incorporated as `Sai Dru Syn Laboratories Limited' at Hyderabad, Telangana (Erstwhile Andhra Pradesh) as a public Limited Company under the Companies Act, 1956, pursuant to a certificate of incorporation dated January 25, 1999, issued by the Registrar of Companies, Andhra Pradesh at Hyderabad. Our Company received the certificate of commencement of business from Registrar of Companies, Andhra Pradesh at Hyderabad on February 17, 1999. Subsequently, the name of our Company was changed from `Sai Dru Syn Laboratories Limited' to `Sai Life Sciences Limited' pursuant to a Shareholders' resolution in an extraordinary general meeting held on December 11, 2003 and a fresh certificate of incorporation dated December 16, 2003 consequent to change of name was issued by the Registrar of Companies, Andhra Pradesh at Hyderabad. Thereafter, the name of the Company was changed from `Sai Life Sciences Limited' to `Sai Advantium Pharma Limited' pursuant to a Shareholders' resolution in an extraordinary general meeting held on August 16, 2006 and a fresh certificate of incorporation dated August 30, 2006 consequent to change of name was issued by the Registrar of Companies, Andhra Pradesh at Hyderabad. Subsequently, the name of our Company was changed from `Sai Advantium Pharma Limited' to its present name, `Sai Life Sciences Limited' pursuant to a Shareholders' resolution in an extraordinary general meeting held on April 20, 2012 and a fresh certificate of incorporation dated May 28, 2012 consequent to change of name was issued by the Registrar of Companies, Andhra Pradesh at Hyderabad.
Amount in ₹ crore
Amount in ₹ crore
Figures in ₹ crore, on a consolidated basis, as reported for FY24 to FY26.